Vulvodynia Treatment Market 2021 | By Key Players, Drug Class , Distribution Channel , Share, Expert Review and Forecast by 2028 | Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc. & so on…
Future Market Insights (FMI) has published a new research report on vulvodynia treatment market. The report has been titled, “Vulvodynia Treatment Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028.” The report states that a recent Harvard study showed that there are approximately 6 million American women who are suffering from vulvodynia. Over 60% of patients’ report of visiting three or more health care providers for diagnosis and an astonishing 40% of patients remain undiagnosed.
This study also reported that 40% of women with painful symptoms did not even seek medical care. Associations such as the National Vulvodynia Association (NVA) are playing a vital role in spreading awareness regarding Vulvodynia treatment. The NVA announced the launch of “Indivisible: Breaking the Silence”, a campaign empowering women with vulvodynia to break their silence and improve the path to diagnosis and treatment.
For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-4985
In order to cater to the need of the growing number of patients, companies are looking out for treatments and drugs that can subside the pain related to vulvodynia. Towards this, they are investing in research and development and mergers and acquisitions. For instance, in January 2016, Merck & Co. Inc., acquired IOmet Pharma Ltd., a privately held U.K.-based drug discovery company focused on the development of innovative medicines for the treatment of cancer. The other leading companies operating in the market are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc, among others.
According to the report, the global vulvodynia treatment market is expected to register a CAGR of 6.1% over the forecast period of 2018 and 2028. The market was worth US$ 4,261.2 Mn in 2017 and is expected to rise to a valuation of US$ 8,091.6 Mn by the end of 2028.
Growing Adoption to Augur Well for Global Market Revenue Growth
The swelling number of patients suffering from vulvodynia and harsh nature of chronic vulvar pain have led to the adoption of early diagnosis and treatment. The adequate results of medical treatments such as drugs, injections and creams have increased the preference for medication to treat vulvodynia. Furthermore, increasing adoption of medicinal treatments of vulvodynia has resulted in an increase in the sales of hormones, local anesthetics, and antidepressants.
Additionally, promising compensation policies in most of the developed countries are also expected to act as a value driver to the growth of the global vulvodynia treatment market. On the other hand, the growing prevalence of the vulvodynia disease among women across the globe is a core factor that is pushing the growth of the vulvodynia treatment market. Vulvodynia is a very common disease in the United States and across the globe. Nevertheless, the ailment remains underdiagnosed or in some cases also incompetently treated.
For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-4985
Lethargic Research and Development for Vulvodynia Treatment Drugs to Slow Down Market Growth
Owing to the absenteeism of detailed information by patients, ignorance of the cause of vulvar pain, and satisfactory results of anticonvulsants and tricyclic antidepressants, researchers are unable to unveil the exact cause of vulvodynia and thereby the R&D on vulvodynia drugs is limited. After anticonvulsants and tricyclic antidepressants, only serotonin and norepinephrine reuptake inhibitors (SNRIs) drugs have showed positive results. Furthermore, if observed, the research and development for vulvodynia treatment is also in a very sluggish phase
Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape
Hyaluronic Acid Products Market FMI’s analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region.
Anti-Osteoporosis Therapy and Fracture Healing Market Find insights into global market scenario and segmentation on the basis of ingredients, application, source and region.
3D Bioprinting Market FMI’s report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period.
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com